Non-invasive point of care fibrosis assessment is central to disease management in viral hepatitis. Today’s noninvasive diagnostic tools support the ability to accurately and painlessly quantify liver health in both the treatment and post-treatment patient. These capabilities can be applied to assessment of treatment need, quantify risk of HCC and portal hypertension and monitor therapeutic response post SVR.
- Understand the role of non-invasive diagnostics in evaluating viral hepatitis patients
- Learn the strengths and weaknesses of primary diagnostic tools in each disease state
- Understand the importance of fibrosis quantification based risk stratification
Non-invasive testing (NIT) is an important and growing field which provides the ability to inexpensively and accurately assess liver fibrosis and steatosis. The role on NIT in liver disease assessment is rapidly evolving to accommodate the needs of NAFLD-NASH disease management.
In this one hour interactive presentation, Dr. Harrison will review the primary oral presentations and abstracts relating to the diagnosis and monitoring of NAFLD through non-invasive testing (NIT) at the point of care, from this years AASLD Liver Meeting.
FibroScan applications in Non-Alcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) presented by Dr. Stephen Harrison.
Sponsored by the Chronic Liver Disease Foundation (CLDF) Dr. Ken Cusi from the University of Florida discusses fatty liver disease in patients with type 2 diabetes.
Dr. Nid Afdhal reviews liver stiffness and CAP assessments with FibroScan across the key etiologies of liver disease.
In this presentation, Dr. Dietrich will review the AGA guidelines as they relate to Elastography and managing chronic liver disease.